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Abstract
Objective—To describe Surveillance, Epidemiology and End Results (SEER) hepatocellular
carcinoma (HCC) incidence trends and United States liver cancer mortality trends by geography,
age, race/ethnicity and gender.
Methods—HCC incidence data from SEER 18 registries and liver cancer mortality data from the
National Center for Health Statistics were analyzed. Rates and joinpoint trends were calculated by
demographic subgroup. State-level liver cancer mortality rates and trends were mapped.
Results—HCC incidence rates in SEER registries did not significantly increase during 2007–
2010, however U.S. liver cancer mortality rates did increase. HCC incidence and liver cancer
mortality rates increased among black, Hispanic and white men aged 50+ years and decreased
among 35–49 year old men in all racial/ethnic groups including Asians/Pacific Islanders.
Significantly increasing incidence and mortality rates among women were restricted to blacks,
Hispanics and whites aged 50+ years. Asian/Pacific Islander liver cancer mortality rates decreased
during 2000–2010 with decreasing rates among women aged 50–64 years and men 35–49 years
and stable rates in other groups. During 2006–2010 among person 50–64 years of age, blacks and
Hispanics had higher incidence and mortality rates than Asians/Pacific Islanders. Liver cancer
mortality rates were highest in Louisiana, Mississippi, Texas and Washington, DC.
Conclusion—Decreasing HCC incidence and liver cancer mortality rates among Asian/Pacific
Islanders, men aged 35–49 years, and the non-significant increase in overall HCC incidence rates
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suggest that the peak of the epidemic may be near or have passed. Findings of geographic
variation in mortality rates can inform control efforts.
Keywords
hepatocellular carcinoma; liver cancer
Introduction
Primary liver cancer is the third largest contributor to cancer mortality in the world (1) and
the seventh largest contributor in the United States (U.S.) (2). The burden of liver cancer in
the U.S. is inequitably distributed by gender, age, and race/ethnicity. Incidence rates of
hepatocellular carcinoma (HCC), the predominant form of liver cancer, and mortality rates
of liver cancer, rise with age and are roughly three times higher among men than women (3).
During 2003–2005 in the National Cancer Institute’s Surveillance, Epidemiology and End
Results (SEER) cancer registries, incidence rates of HCC were more than three times higher
among Asians/Pacific Islanders than whites, with intermediate rates among Hispanics,
blacks and American Indians/Alaska Natives (4). U.S. liver cancer mortality rates mirror
HCC incidence rates, reflecting the poor survival of this cancer. In many countries,
including the U.S., HCC incidence rates and liver cancer mortality rates have been
increasing for decades. Between 1992 and 2005, HCC incidence rates in SEER registries
increased from 3.1 to 5.1 per 100,000 persons, and United States liver cancer mortality rates
rose from 3.3 to 4.0 per 100,000 persons (4).
Models based on the prevalence of an important cause of liver cancer in the U.S., chronic
infection with hepatitis C virus (HCV), have predicted that HCC incidence will continue to
climb for the next several decades (5). However, these models have not considered the
changing prevalence of HCV and other risk factors (3). Whether predicted models of HCC
trends are accurate remains uncertain. To characterize trends in the U.S. in the early 21st
century, HCC incidence and liver cancer mortality rates were examined by demographic
characteristics.
Methods
Incidence
Cancer incidence data during 2000–2010 were obtained from all 18 SEER registries, which
cover 28% of the U.S. population (6). Liver cancer incidence was defined by International
Classification of Diseases for Oncology, Third Edition (7) using topography codes C22.0
and C22.1. HCC cases were restricted to morphology codes 8170–8175. Of 87,988
malignant liver and intrahepatic cancer diagnoses reported during 2000–2010 in SEER 18
registries, 63,735 (72%) were classified as HCCs.
Mortality
United States data on cause of mortality during the years 2000–2010 were reported by the
Centers for Disease Control and Prevention, National Center for Health Statistics (8). Deaths
due to liver cancer were identified by International Classification for Diseases version 10
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codes for the underlying cause of death (9), using codes C22.0–C22.9 (malignant neoplasm
of liver and intrahepatic bile ducts), excluding C22.1 (intrahepatic bile duct cancer). To
improve completeness of classification, mortality rates among Hispanics and non-Hispanics
were restricted to areas that met data quality measures for reporting of Hispanic ethnicity,
thereby excluding the populations of New Hampshire, North Dakota, South Carolina, and
Washington, D.C which account for approximately 2% of the U.S. population (10). The
current analysis was based on 138,326 reported liver cancer deaths, after excluding 27,203
intrahepatic bile duct cancer deaths. Sensitivity analyses of mortality trends that restricted
cases and populations to SEER registry areas were performed.
Populations
Data on HCC incidence and liver cancer mortality were linked to Census Bureau population
denominator data for 2000 through 2010, with data by geographic location, gender, age, and
race/ethnicity (non-Hispanic white, black, Asian/Pacific Islander, and Hispanic) (11).
American Indians/Alaska Natives were not included in the current study as small counts
yielded unstable rate estimates.
Statistical analysis
Average annual HCC incidence and liver cancer mortality rates per 100,000 persons were
estimated for the most recent five-year period of diagnoses, 2006–2010 (SEER*Stat v 7.0.9,
Information Management Services; Silver Spring, MD). Rates were age-adjusted by the
direct method to the 2000 US standard population (19 age groups) (12). Rates and trends
were examined by age group (overall, 35–49, 50–64 and 65+ years of age), gender, non-
Hispanic race and Hispanic ethnicity. Joinpoint regression (13) allowing two segments was
used to fit age-adjusted trends for 2000–2010 (Joinpoint v 3.5, Information Management
Services; Silver Spring, MD). Annual percent change (APC) was considered statistically
significant when the regression line slope differed from zero (P<0.05).
State-specific liver cancer mortality rates per 100,000 persons during 2006–2010 were age-
adjusted by the direct method to the 2000 US standard population (19 age groups) (12).
Maps of overall liver cancer mortality rates used the Jenks natural break classification
method (14) to yield six categories: states with 2.3 to 2.9 deaths per 100,000 (5 states), 3.0
to 3.5 deaths per 100,000 (11 states), 3.6 to 4.0 deaths per 100,000 (13 states), 4.1 to 4.5
deaths per 100,000 (12 states), 4.6 to 5.5 deaths per 100,000 (6 states), and 5.6 to 6.8 deaths
per 100,000 (3 states and Washington, D.C.).
Maps of liver cancer mortality rate trends for age groups 35–49, 50–64, and 65+ years of
age, based on a single joinpoint segment model for the period 2000–2010 categorized states
into five groups, based on criteria used in the National Cancer Institute’s Cancer Trends
Progress Report (15). Group 1: Significant decrease (Rate decreasing, statistically
significant annual percentage change (APC)); Group 2: Non-significant decrease (Rate
decrease more than −0.5% per year, APC not statistically significant); Group 3: Stable
(Absolute value of rate change less than or equal to 0.5% per year, APC not statistically
significant); Group 4: Non-significant increase (Rate increase over 0.5% per year, APC not
statistically significant); and Group 5: Significant increase (Rate increasing with a
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statistically significant APC). National mortality trends for two underlying causes of liver
cancer 1) liver disease and cirrhosis and 2) diabetes mellitus were compared with those for
liver cancer. Using the five-category trend variable correlations with state-level mortality
trends were examined with the CORR procedure (SAS v 9.3, Cary, NC). State-level maps of
liver cancer mortality rates and trends were drawn using ArcMap 10.0 (ESRI, Redlands,
CA).
Results
HCC incidence
As shown in Table 1, HCC incidence increased with age in all racial/ethnic groups in the
interval 2006–2010, with the exception of blacks, for whom rates were higher among
persons 50–64 than 65+ years of age. (All reported incidence rates are per 100,000 people).
Overall, Asians and Pacific Islanders had the highest incidence rates, followed by Hispanics,
blacks and lastly, whites. Among persons aged 35–49 years, Asians and Pacific Islanders
had the highest HCC incidence rate (4.7), followed by Hispanics (3.2), blacks (2.5), and
whites (1.4). Among persons aged 50–64 years, blacks had the highest incidence rate (26.9),
followed by Hispanics (24.3), Asians and Pacific Islanders (23.5) and whites (12.2). The
very highest age-specific rates were experienced by Asians and Pacific Islanders aged 65+
years (54.7 per 100,000).
Between 2000 and 2010, incidence significantly increased, by 5.4% per year during 2000–
2007, then non-significantly by 2.3% per year during 2007–2010 (Figure 1a). Among
persons aged 35–49 years, incidence rates non-significantly decreased by 1.4% per year
during 2000–2010. Among persons aged 50–64 years, rates significantly increased by 9.6%
per year from 2000 to 2006, then by 5.2% per year from 2006 to 2010. Among persons 65
years+, rates increased 3.6% per year during 2000–2010.
Overall rates significantly increased among whites during 2000–2008 (5.9% per year), then
non-significantly increased by 1.3% per year during 2008–2010 (Table 2). Overall rates
increased during 2000–2010 among blacks and Hispanics (5.6% and 3.3% per year
respectively). Among Asians/Pacific Islanders overall rates non-significantly increased
during 2000–2002 (8.2% per year) followed by a period of borderline statistically significant
decrease during 2002–2010 (−1.2% per year).
HCC incidence trends by race, age and gender are shown in Figure 2. Age- and race-specific
rates were higher among men than women. Significantly increasing trends occurred only
among Hispanic, white, and black men and women ages 50–64 and 65+ years, with the
exception of a stable trend among Hispanic women aged 65+ years. Rates were also stable
among Asian/Pacific Islander women aged 65+ years and women aged 35–49 years in all
racial/ethnic groups. Among men rates were stable for Asian/Pacific Islanders aged 50–64
and 65+ years. Significantly decreasing HCC incidence rates were experienced among
Asian/Pacific Islander, white and black men aged 35–49 years, with a borderline statistically
significant decrease among Hispanic men in this age group. Among women, rates
significantly declined only for Asian/Pacific Islanders aged 50–64 years. APCs and
confidence intervals for HCC incidence trends are presented in Table 3A.
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Liver cancer mortality
Between 2006 and 2010, U.S. liver cancer mortality rates increased with age in all racial/
ethnic groups (Table 1). (All reported mortality rates are per 100,000 people). Among
persons aged 35–49 years, Asians/Pacific Islanders had the highest mortality rates (2.8),
followed by blacks (2.0), Hispanics (1.4), and whites (0.9). Among persons aged 50–64
years, blacks had the highest mortality rate (18.6), followed by Hispanics (13.5), Asians/
Pacific Islanders (13.0) and whites (7.7). Mortality rates were highest among Asians/Pacific
Islanders aged 65+ years (43.2 per 100,000).
As shown in Figure 1b, overall liver cancer mortality rates significantly increased during
2000–2010 (APC=2.1%), with a less rapid increase among persons aged 65+ years
(APC=1.1%) than among persons aged 50–64 years (APC=5.6%). There was a significant
decrease, however, among persons aged 35–49 years (APC=−3.2%).
United States liver cancer mortality trends by race/ethnic group during 2000–2010 are
shown in Table 2B. Overall rates significantly increased during 2000–2010 among whites,
blacks and Hispanics (2.1%, 2.4% and 1.3% per year respectively), however rates among
Asians/Pacific Islanders significantly decreased (−1.6% per year). Sensitivity analyses
restricted to SEER areas revealed mortality trends comparable to U.S. patterns in both
magnitude and statistical significance (data not shown).
United States liver cancer mortality trends by race, age and gender are shown in Figure 3.
Age- and race-specific rates were higher among men than women. Significantly increasing
trends occurred only among Hispanic, white and black men aged 50–64 and 65+ years,
Hispanic women aged 65+ years, and black and white women aged 50–64 years. Mortality
rates did not significantly change for women in other population subgroups except for
decreasing trends among black women aged 35–49 years and Asian/Pacific Islander women
aged 50–64 years. Among men, mortality rates were stable for Asian/Pacific Islanders aged
50–64 and 65+ years and significantly decreased among Asian/Pacific Islander, black,
Hispanic and white men aged 35–49 years. APCs and confidence intervals for these trends
are presented in Table 3B.
State-specific liver cancer mortality rates
Figure 4 presents state-specific liver cancer mortality rates, which ranged from 2.3 to 6.8.
The highest rates (5.5–6.8) were experienced by the populations of Washington, D.C. and
three Gulf Coast states (Louisiana, Mississippi, and Texas). The second highest rates were
reported in Alabama, Arkansas, California, Hawaii, Nevada, and New Mexico. Coastal,
Appalachian, and Midwestern states generally reported higher rates than states in the
Northern Plains and Northern Rocky Mountains. Confidence intervals for these rates are
presented in Table 4
State-specific liver cancer mortality trends
When state-specific liver cancer mortality trends during 2000–2010 were examined by age
group, striking age-specific patterns were seen (Figure 5). Among persons aged 35–49 years,
rates significantly decreased in 12 states and non-significantly decreased in 23 states and
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Washington, D.C., with no state experiencing a significant increase (Figure 5A). In contrast,
among persons aged 50–64 years, rates significantly increased in 41 states and Washington,
D.C. with no state experiencing a significant decrease (Figure 5B). Rates among persons
aged 65+ years significantly increased in California, Arizona, Oklahoma, Florida, Georgia,
Virginia, the District of Columbia, Delaware, New York, Vermont, and Massachusetts and
significantly decreased in Alaska (Figure 5C).
Table 5 presents national mortality trends for liver cancer and two underlying causes of liver
cancer 1) chronic liver disease and cirrhosis and 2) diabetes mellitus. The direction of liver
cancer mortality trends were consistent with those for chronic liver disease and cirrhosis in
35–49 year olds, for whom both causes of death significantly decreased and 50–64 year
olds, for whom both causes of death are significantly increased. There was also a
statistically significant correlation between the liver cancer and chronic liver disease,
cirrhosis trends among persons 50–64 year of age, P=0.03.
Discussion
After decades of statistically significant increasing HCC incidence rates, during 2007–2010
the trend was no longer statistically significant. The change was partly explained by
decreasing incidence rates among Asians/Pacific Islanders, the racial group most affected by
HCC, and among men aged 35–49 years. Incidence rates only increased among black,
Hispanic and white men and women aged 50+ years. Geographic variation in liver cancer
mortality suggests a need for focused liver cancer control efforts in southern and coastal
states. Across states, increases in liver cancer mortality rates were most often seen among
persons aged 50–64 years (baby-boomers) and decreasing rates occurred primarily among
persons in the next generation, aged 35–49 years. These findings support the hypothesis that
HCC incidence and liver cancer mortality trends vary across race, ethnicity, age, gender and
geographic groups.
HCC incidence trends are affected by the changing prevalence of risk factors. In the U.S. a
leading risk factor is hepatitis C virus (HCV) infection (16), particularly among person born
between 1945 and 1965, commonly referred to as “baby-boomers” (17). Other HCC risk
factors include chronic hepatitis B virus (HBV) infection (18), obesity (19), diabetes (20),
non-alcoholic fatty liver disease (NAFLD) (21), and excessive alcohol use (22), all of which
occur at variable frequencies across socio-demographic sectors of the population (23–27).
Each of these factors predisposes to cirrhosis, the precursor of most HCC. In the past,
persons with cirrhosis tended to die from the disease. As treatment has improved, however,
the risk of death from cirrhosis has declined and, as a consequence, the risk HCC developing
among persons with cirrhosis may be increasing (28).
Consistent with prior studies of HCC incidence in the United States, the continuing increase
in U.S. liver cancer mortality rates was driven by increasing trends among blacks, whites,
and Hispanics (4, 29, 30). In this report, liver cancer mortality rates among adults aged 50–
64 years were significantly higher for blacks than other racial/ethnic groups. While not
statistically significant, for the first time, Hispanics aged 50–64 years had higher HCC
incidence and liver cancer mortality rates than Asians/Pacific Islanders. Better estimates of
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the fraction of HCC cases in affected subgroups attributable to specific etiologies would
facilitate screening of people at-risk.
Compared to other racial groups, liver cancer incidence historically has been elevated
among Asians/Pacific Islanders. This is attributed to the high rate of chronic HBV infection
among older adults who were born outside the United States (16). A previous report
observed that liver cancer mortality rates among Asians/Pacific Islanders declined 0.9% per
year from 1992–2005 (4). The present report found a more rapid rate of decline (−1.6%)
during 2000–2010. Cultural awareness of liver cancer risk may incentivize HBV and liver
cancer screening and related therapies in this racial group that will further decrease liver
cancer mortality rates.
Declining liver cancer mortality rates among young adults, ages 35–49 years may signal a
future decline in overall U.S. liver cancer mortality rates. This was the case in Japan, where
liver cancer mortality peaked a generation earlier than in the United States among the
Japanese birth cohort born during 1925–1939 (35, 36). A decrease in Japanese liver cancer
mortality began around 1985, and was first evident in the sentinel group of young adults,
about 40 years of age (36). The reversal of liver cancer mortality trends in Japan has been
attributed to declining exposure to HCV-related risk factors that included injected drug use
and contaminated blood product transfusion in the post-World War II era (36).
Recent HCV screening guidelines for persons born during 1945–1965 (17) combined with
advances in treatment of HCV infection (31, 32) and guidelines for HCC screening and
therapy (33) may accelerate progress in reducing U.S. liver cancer mortality rates. While 3.2
million people in the U.S. currently have chronic HCV infection, the rate of new infection
has greatly decreased (17, 34). Until recently, the standard of care for HCV-infected persons
consisted of lengthy treatment with interferon and ribavirin. Historically, treatment has been
a challenge due to limited treatment success and discontinuation due to adverse effects.
Progress has been made, however, and future regimens are likely to incorporate multiple
direct-acting antiviral drugs. In 2011, the FDA approved two direct-acting antiviral agents
for persons infected with HCV genotype 1: telaprevir and boceprevir (31). In addition, there
are other promising drugs in development that target HCV encoded proteins. At present,
prescribed drug regimens cure approximately 80% of HCV patients. While cost of treatment
remains an impediment, improving treatments could have a considerable downward effect
on future HCC incidence rates, particularly among the baby-boomer cohort.
In the present study, United States liver cancer mortality rates continued a statistically
significant rise while the increase in HCC incidence rates in SEER registries was no longer
statistically significant. Several factors could explain the discrepancy. Mortality statistics
cover 98% of the U.S., while SEER registries cover 28% and areas with the highest
mortality rates including Texas, Mississippi and the District of Columbia are not in the
SEER catchment. Underlying trends may differ between the U.S. and SEER areas.
Secondly, liver cancer mortality data are based on the underlying causes of death on death
certificates. When the cause of death is not fully documented, it can result in an undercount.
Such errors are less likely with cancer incidence data, which are based on detailed
abstractions of medical records. Thirdly, although HCC is the dominant histologic type of
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liver cancer, it is not the sole type, and rarer types do contribute to mortality rates. In
addition, the liver is a common site of metastasis, thus some secondary liver cancers could
be mistakenly over counted as primary liver cancer. Despite these potential sources of
misclassification, incidence and mortality trends in SEER areas generally mirrored U.S.
mortality trends.
As this is the first year in decades during which recent HCC incidence rates did not
significantly increase, caution is warranted against over-interpretation. HCC incidence rates
should be monitored over time to assess whether the direction of the trend turns downward,
remains constant or increases. Strengths of the current study include the ability to examine
HCC incidence in 28% and liver cancer mortality in 98% of the United States population by
age, sex, and race/ethnicity. Limitations include the absence of data on etiological risk
factors. Despite limitations, the data provide insight into changes in HCC incidence and liver
cancer mortality rates across demographic strata of the United States population.
In summary, while overall liver cancer mortality rates increased during 2000–2010, recent
HCC incidence rates did not significantly increase. Decreasing mortality rates among adult
men aged 35–49 years and Asians/Pacific Islanders suggest that the peak of the epidemic
may be near or have passed. Findings of geographically variable liver cancer mortality rates
may help target affected areas.
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Study Highlights
1. What is current knowledge?
• United States hepatocellular carcinoma (HCC) incidence and liver cancer
mortality rates increased since the 1980s, with higher rates among men than
women.
• Rates are higher among Asians and Pacific Islanders than whites, with
intermediate rates among Hispanics, blacks.
2. What is new here?
• Incidence and mortality rates only increased among men who were black,
Hispanic or white and 50+ years of age and among most women in these
population subgroups. These increases were most pronounced among “baby-
boomers”, 50–64 years of age.
• During 2000–2010 age- and gender-specific incidence and mortality rates were
stable or decreased among Asians/Pacific Islander age and gender subgroups.
• Black and Hispanic baby-boomers now have higher incidence and mortality
rates than Asian/Pacific Islander men of the same age.
• Incidence and mortality rates decreased among 35–49 year old men in all four
racial and ethnic groups.
• Recent liver cancer mortality rates were higher in southern and coastal states
than other areas.
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Figure 1.
Age-adjusted SEER 18 HCC incidence and U.S. liver cancer mortality rates by age group
and year; 2000–2010
CI=confidence interval
Trend = annual percent change, or APC. Joinpoint regression defines when a trend changes.
Up to one joinpoint allowed in the eleven year period.
* Asterisk indicates slope of trend differs from zero (P<0.05)
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Figure 2.
Age-adjusted HCC incidence rates per 100,000 by age group, gender, non-Hispanic race and
Hispanic ethnicity, SEER 18 registries -- 2000–2010
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Figure 3.
Age-adjusted liver cancer mortality rates per 100,000 by age group, gender, non-Hispanic
race and Hispanic ethnicity, United States -- 2000–2010
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Figure 4.
Age-adjusted liver cancer mortality rates per 100,000 by state, 2006–2010
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Figure 5.
Annual percent change (APC) in liver cancer mortality rates by state, 2000 to 2010 by age
group: (A) 35 to 49, (B) 50 to 64 and (C) 65+ years of age
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Table 4
Liver Cancer Mortality Rate per 100,000 people, 2006–2010
State/District Rate per 100,000 95% CI*
Washington, DC 6.8 (5.9, 7.8)
Louisiana 6.4 (6.1, 6.8)
Mississippi 6.0 (5.6, 6.4)
Texas 6.0 (5.9, 6.2)
Hawaii 5.5 (5, 6.1)
California 5.4 (5.3, 5.5)
Arkansas 5.3 (4.9, 5.7)
Nevada 4.9 (4.5, 5.3)
Alabama 4.8 (4.6, 5.1)
New Mexico 4.8 (4.4, 5.2)
Delaware 4.5 (3.9, 5.1)
Florida 4.4 (4.3, 4.5)
Massachusetts 4.4 (4.2, 4.6)
Oklahoma 4.4 (4.1, 4.7)
Tennessee 4.4 (4.2, 4.6)
Arizona 4.3 (4.1, 4.6)
New York 4.3 (4.2, 4.4)
Maryland 4.2 (3.9, 4.4)
Washington 4.2 (4, 4.5)
Georgia 4.1 (3.9, 4.3)
Rhode Island 4.1 (3.6, 4.7)
South Carolina 4.1 (3.9, 4.4)
Illinois 4.0 (3.8, 4.1)
Michigan 4.0 (3.9, 4.2)
Missouri 4.0 (3.8, 4.3)
New Jersey 3.9 (3.7, 4.1)
Oregon 3.9 (3.6, 4.2)
Virginia 3.9 (3.7, 4.1)
Kentucky 3.8 (3.5, 4)
Pennsylvania 3.8 (3.7, 3.9)
Vermont 3.8 (3.2, 4.6)
Alaska 3.7 (3, 4.5)
North Carolina 3.7 (3.5, 3.9)
Ohio 3.6 (3.4, 3.7)
Wyoming 3.6 (3, 4.4)
Indiana 3.5 (3.3, 3.7)
Colorado 3.4 (3.1, 3.6)
Connecticut 3.4 (3.1, 3.7)
Kansas 3.3 (3, 3.6)
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State/District Rate per 100,000 95% CI*
West Virginia 3.3 (3, 3.7)
Wisconsin 3.3 (3.1, 3.5)
Maine 3.1 (2.8, 3.5)
Minnesota 3.1 (2.9, 3.4)
New Hampshire 3.1 (2.7, 3.5)
Iowa 3.0 (2.7, 3.2)
Nebraska 3.0 (2.6, 3.3)
Montana 2.9 (2.5, 3.4)
South Dakota 2.8 (2.3, 3.3)
Idaho 2.7 (2.3, 3.1)
Utah 2.7 (2.4, 3.1)
North Dakota 2.3 (1.8, 2.8)
*CI=Confidence Interval
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